PharmacoEconomics

1997 - 2025

Current editor(s): Timothy Wrightson and Christopher I. Carswell

From Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().

Access Statistics for this journal.
Is something missing from the series or not right? See the RePEc data check for the archive and series.

Volume 31, issue 12, 2013

Search MEDLINE for Economic Evaluations: Tips to Translate an OVID Strategy into a PubMed One pp. 1087-1090

Mattias Neyt and Patrice Chalon

Assessing the Cost Effectiveness of Pre-Exposure Prophylaxis for HIV Prevention in the US pp. 1091-1104

Fred Hellinger

How to Include Informal Care in Economic Evaluations pp. 1105-1119

Renske Hoefman, Job van Exel and Werner Brouwer

Vemurafenib for the Treatment of Locally Advanced or Metastatic BRAF V600 Mutation-Positive Malignant Melanoma: A NICE Single Technology Appraisal pp. 1121-1129

Sophie Beale, Rumona Dickson, Adrian Bagust, Michaela Blundell, Yenal Dundar, Angela Boland, Ernie Marshall, Ruth Plummer and Chris Proudlove

The Estimation of Utility Weights in Cost-Utility Analysis for Mental Disorders: A Systematic Review pp. 1131-1154

Michael Sonntag, Hans-Helmut König and Alexander Konnopka

Cost Effectiveness of Medication Adherence-Enhancing Interventions: A Systematic Review of Trial-Based Economic Evaluations pp. 1155-1168

Edwin Oberjé, Reina Kinderen, Silvia Evers, Cees Woerkum and Marijn Bruin

A Closer Look at Decision and Analyst Error by Including Nonlinearities in Discrete Choice Models: Implications on Willingness-to-Pay Estimates Derived from Discrete Choice Data in Healthcare pp. 1169-1183

Esther Bekker-Grob, John Rose and Michiel Bliemer

Erratum to: Cost–Utility Analysis of Deferiprone for the Treatment of β-Thalassaemia Patients with Chronic Iron Overload: A UK Perspective pp. 1185-1186

Anthony Bentley, Samantha Gillard, Michael Spino, John Connelly and Fernando Tricta

Volume 31, issue 11, 2013

Antiplatelet Therapy in Patients Undergoing Percutaneous Coronary Intervention: Economic Considerations pp. 959-970

William Weintraub, Leonid Mandel and Sandra Weiss

Cost Effectiveness of Treatments for Stroke Prevention in Atrial Fibrillation: Focus on the Novel Oral Anticoagulants pp. 971-980

Charalampos Kasmeridis, Stavros Apostolakis, Lars Ehlers, Lars Rasmussen, Giuseppe Boriani and Gregory Lip

Aripiprazole for the Treatment and Prevention of Acute Manic and Mixed Episodes in Bipolar I Disorder in Children and Adolescents: A NICE Single Technology Appraisal pp. 981-990

Lesley Uttley, Ben Kearns, Shijie Ren and Matt Stevenson

Methods to Elicit Probability Distributions from Experts: A Systematic Review of Reported Practice in Health Technology Assessment pp. 991-1003

Bogdan Grigore, Jaime Peters, Christopher Hyde and Ken Stein

Systematic Literature Review of the Costs of Pregnancy in the US pp. 1005-1030

Lynn Huynh, Mark McCoy, Amy Law, Kevin Tran, Senta Knuth, Patrick Lefebvre, Sean Sullivan and Mei Duh

A Methodological Review of Models Used to Estimate the Cost Effectiveness of Antiretroviral Regimens for the Treatment of HIV Infection pp. 1031-1050

Josephine Mauskopf

Eliciting Preferences for Prioritizing Treatment of Rare Diseases: the Role of Opportunity Costs and Framing Effects pp. 1051-1061

Arna Desser, Jan Olsen and Sverre Grepperud

The Availability, Pricing and Affordability of Three Essential Asthma Medicines in 52 Low- and Middle-Income Countries pp. 1063-1082

Zaheer-Ud-Din Babar, Charon Lessing, Cécile Mace and Karen Bissell

Volume 31, issue 10, 2013

Ruxolitinib for the Treatment of Myelofibrosis: A NICE Single Technology Appraisal pp. 841-852

Ros Wade, Micah Rose, Aileen Neilson, Lisa Stirk, Rocio Rodriguez-Lopez, David Bowen, Dawn Craig and Nerys Woolacott

Using the Stated Preference Technique for Eliciting Valuations: The Role of the Payment Vehicle pp. 853-861

Dorte Gyrd-Hansen

The Road Not Taken: Transferability Issues in Multinational Trials pp. 863-876

Pepijn Vemer and Maureen Rutten- van Mölken

Patient Preferences for the Treatment of Type 2 Diabetes: A Scoping Review pp. 877-892

Susan Joy, Emily Little, Nisa Maruthur, Tanjala Purnell and John Bridges

A Person Trade-Off Study to Estimate Age-Related Weights for Health Gains in Economic Evaluation pp. 893-907

Stavros Petrou, Ngianga-Bakwin Kandala, Angela Robinson and Rachel Baker

Cost-Effectiveness of Rivaroxaban Versus Warfarin for Stroke Prevention in Atrial Fibrillation in the Belgian Healthcare Setting pp. 909-918

Joris Kleintjens, Xiao Li, Steven Simoens, Vincent Thijs, Marnix Goethals, Ernst Rietzschel, Yumi Asukai, Ömer Saka, Thomas Evers, Petra Faes, Stefaan Vansieleghem and Mimi Ruyck

Cost-Effectiveness Analysis of Triple Therapy with Protease Inhibitors in Treatment-Naive Hepatitis C Patients pp. 919-931

Antonio Blázquez-Pérez, Ramón San Miguel and Javier Mar

Projecting Expenditure on Medicines in the UK NHS pp. 933-957

Phill O’Neill, Jorge Mestre-Ferrandiz, Ruth Puig-Peiro and Jon Sussex

Volume 31, issue 9, 2013

Navigating Time and Uncertainty in Health Technology Appraisal: Would a Map Help? pp. 731-737

Christopher McCabe, Richard Edlin and Peter Hall

Protease Inhibitors for Hepatitis C: Economic Implications pp. 739-751

Stuart Turner, Jack Brown and Joseph Paladino

The Economic Burden of Toxicities Associated with Cancer Treatment: Review of the Literature and Analysis of Nausea and Vomiting, Diarrhoea, Oral Mucositis and Fatigue pp. 753-766

Alan Carlotto, Virginia Hogsett, Elyse Maiorini, Janet Razulis and Stephen Sonis

Smoking Cessation Treatment and Outcomes Patterns Simulation: A New Framework for Evaluating the Potential Health and Economic Impact of Smoking Cessation Interventions pp. 767-780

Denis Getsios, Jenő Marton, Nikhil Revankar, Alexandra Ward, Richard Willke, Dale Rublee, K. Ishak and James Xenakis

Unravelling Drug Reimbursement Outcomes: A Comparative Study of the Role of Pharmacoeconomic Evidence in Dutch and Swedish Reimbursement Decision Making pp. 781-797

Margreet Franken, Fredrik Nilsson, Frank Sandmann, Anthonius Boer and Marc Koopmanschap

Costs of Parkinson’s Disease in a Privately Insured Population pp. 799-806

Scott Johnson, Anna Kaltenboeck, Melissa Diener, Howard Birnbaum, ElizaBeth Grubb, Jane Castelli-Haley and Andrew Siderowf

Cost–Utility Analysis of Deferiprone for the Treatment of β-Thalassaemia Patients with Chronic Iron Overload: A UK Perspective pp. 807-822

Anthony Bentley, Samantha Gillard, Michael Spino, John Connelly and Fernando Tricta

Cost Effectiveness of Moderate to Severe Psoriasis Therapy with Etanercept and Ustekinumab in the United States pp. 823-839

Reginald Villacorta, Joel Hay and Andrew Messali

Volume 31, issue 8, 2013

Constructing Indirect Utility Models: Some Observations on the Principles and Practice of Mapping to Obtain Health State Utilities pp. 635-641

Christopher McCabe, Richard Edlin, David Meads, Chantelle Brown and Samer Kharroubi

Good Practice Guidelines for the use of Statistical Regression Models in Economic Evaluations pp. 643-652

Ben Kearns, Roberta Ara, Allan Wailoo, Andrea Manca, Monica Alava, Keith Abrams and Mike Campbell

Golimumab for the Treatment of Rheumatoid Arthritis After the Failure of Previous Disease-Modifying Antirheumatic Drugs: A NICE Single Technology Appraisal pp. 653-661

Jonathan Tosh, Rachel Archer, Sarah Davis, Matt Stevenson and John Stevens

Overview of Parametric Survival Analysis for Health-Economic Applications pp. 663-675

K. Ishak, Noemi Kreif, Agnes Benedict and Noemi Muszbek

Incorporating Process Utility into Quality Adjusted Life Years: A Systematic Review of Empirical Studies pp. 677-691

Victoria Brennan and Simon Dixon

Understanding the Cost-Effectiveness of Influenza Vaccination in Children: Methodological Choices and Seasonal Variability pp. 693-702

Anthony Newall, Juan Dehollain, Prudence Creighton, Philippe Beutels and James Wood

Real-World Cost-Effectiveness of Oxaliplatin in Stage III Colon Cancer: A Synthesis of Clinical Trial and Daily Practice Evidence pp. 703-718

Chantal Gils, Saskia Groot, William Redekop, Miriam Koopman, Cornelis Punt and Carin Uyl- de Groot

A Choice That Matters? pp. 719-730

Pepijn Vemer, Maiwenn Al, Mark Oppe and Maureen Rutten- van Mölken

Volume 31, issue 7, 2013

Dabigatran for the Prevention of Stroke and Systemic Embolism in Atrial Fibrillation: A NICE Single Technology Appraisal pp. 551-562

Rita Faria, Eldon Spackman, Jane Burch, Belen Corbacho, Derick Todd, Chris Pepper, Nerys Woolacott and Stephen Palmer

A Comparative Analysis of Models Used to Evaluate the Cost-Effectiveness of Dabigatran Versus Warfarin for the Prevention of Stroke in Atrial Fibrillation pp. 589-604

Sonja Sorensen, Siyang Peng, Brigitta Monz, Carole Bradley-Kennedy and Anuraag Kansal

The Development and Validation of a Decision-Analytic Model Representing the Full Disease Course of Acute Myeloid Leukemia pp. 605-621

Annemieke Leunis, W. Redekop, Kees van Montfort, Bob Löwenberg and Carin Uyl- de Groot

Volume 31, issue 6, 2013

Modelling the Cost Effectiveness of Disease-Modifying Treatments for Multiple Sclerosis pp. 455-469

Joel Thompson, Amir Abdolahi and Katia Noyes

Trabectedin for the Treatment of Advanced Metastatic Soft Tissue Sarcoma: A NICE Single Technology Appraisal pp. 471-478

Rachid Rafia, Emma Simpson, Matt Stevenson and Diana Papaioannou

Cabazitaxel for the Second-Line Treatment of Metastatic Hormone-Refractory Prostate Cancer: A NICE Single Technology Appraisal pp. 479-488

Ben Kearns, Myfanwy Lloyd Jones, Matt Stevenson and Chris Littlewood

Disutility of Illness for Caregivers and Families: A Systematic Review of the Literature pp. 489-500

Eve Wittenberg and Lisa Prosser

Transferability of Indirect Cost of Chronic Disease: A Systematic Review and Meta-Analysis pp. 501-508

Fei-Li Zhao, Feng Xie, Hao Hu and Shu-Chuen Li

Simulating Lifetime Outcomes Associated with Complications for People with Type 1 Diabetes pp. 509-518

Tom Lung, Philip Clarke, Alison Hayes, Richard Stevens and Andrew Farmer

Cost Effectiveness of Targeted High-dose Atorvastatin Therapy Following Genotype Testing in Patients with Acute Coronary Syndrome pp. 519-531

Anju Parthan, Kevin Leahy, Amy O’Sullivan, Olga Iakoubova, Lance Bare, James Devlin and Milton Weinstein

A Comment on Craig et al.: ‘‘Retigabine for the Adjunctive Treatment of Adults with Partial-Onset Seizures in Epilepsy with and without Secondary Generalization: A NICE Single Technology Appraisal’’ pp. 533-535

Przemysław Holko and Paweł Kawalec

Volume 31, issue 5, 2013

How Much Should the NHS Pay for a QALY? pp. 357-359

Alan Haycox

Consolidated Health Economic Evaluation Reporting Standards (CHEERS) Statement pp. 361-367

Don Husereau, Michael Drummond, Stavros Petrou, Chris Carswell, David Moher, Dan Greenberg, Federico Augustovski, Andrew Briggs, Josephine Mauskopf and Elizabeth Loder

Pharmacoeconomic Guidelines Should Prescribe Inclusion of Indirect Medical Costs! A Response to Grima et al pp. 369-373

Pieter Baal, David Meltzer and Werner Brouwer

The Authors’ Reply to van Baal et al.: “Pharmacoeconomic Guidelines Should Prescribe Inclusion of Indirect Medical Costs! A Response to Grima et al.” pp. 375-376

Daniel Grima, Lisa Bernard, Elizabeth Dunn, Philip McFarlane and David Mendelssohn

Review of the Cost Effectiveness of Pharmacogenetic-Guided Treatment of Hypercholesterolaemia pp. 377-391

Michael Sorich, Michael Wiese, Rebekah O’Shea and Brita Pekarsky

Optimal Global Value of Information Trials: Better Aligning Manufacturer and Decision Maker Interests and Enabling Feasible Risk Sharing pp. 393-401

Simon Eckermann and Andrew Willan

Rituximab for the First-Line Maintenance Treatment of Follicular Non-Hodgkin’s Lymphoma pp. 403-413

Janette Greenhalgh, Adrian Bagust, Angela Boland, Michaela Blundell, James Oyee, Sophie Beale, Yenal Dundar, Juliet Hockenhull, Chris Proudlove and Patrick Chu

Golimumab for the Treatment of Ankylosing Spondylitis: A NICE Single Technology Appraisal pp. 415-425

Nigel Armstrong, Manuela Joore, Thea Asselt, Kate Misso, Nathan Manning, Florian Tomini, Jos Kleijnen and Rob Riemsma

Lopinavir/Ritonavir Versus Darunavir Plus Ritonavir for HIV Infection: A Cost-Effectiveness Analysis for the United States pp. 427-444

Kit Simpson, Pamela Pei, Jörgen Möller, Robert Baran, Birgitta Dietz, William Woodward, Kristen Migliaccio-Walle and J. Caro

The Determinants of Cost-Effectiveness Potential: An Historical Perspective on Lipid-Lowering Therapies pp. 445-454

Rodrigo Refoios Camejo, Clare McGrath, Marisa Miraldo and Frans Rutten

Volume 31, issue 4, 2013

Korean Guidelines for Pharmacoeconomic Evaluation (Second and Updated Version) pp. 257-267

SeungJin Bae, SooOk Lee, Eun Bae and Sunmee Jang

Bivalirudin for the Treatment of ST-Segment Elevation Myocardial Infarction: A NICE Single Technology Appraisal pp. 269-275

E. Simpson, P. Fitzgerald, P. Evans, P. Tappenden, N. Kalita, J. Reckless and A. Bakhai

A Systematic Review of Utility Values for Chemotherapy-Related Adverse Events pp. 277-288

Fatiha Shabaruddin, Li-Chia Chen, Rachel Elliott and Katherine Payne

Model-Based Cost-Effectiveness Analyses for Prostate Cancer Chemoprevention pp. 289-304

Stephanie Earnshaw, Andrew Brogan and Cheryl McDade

Using a Discrete Choice Experiment to Elicit Time Trade-Off and Willingness-to-Pay Amounts for Influenza Health-Related Quality of Life at Different Ages pp. 305-315

Lisa Prosser, Katherine Payne, Donna Rusinak, Ping Shi and Mark Messonnier

The Cost Effectiveness of Pharmacological Treatments for Generalized Anxiety Disorder pp. 317-333

Ifigeneia Mavranezouli, Nick Meader, John Cape and Tim Kendall

Temporary Authorization for Use: Does the French Patient Access Programme for Unlicensed Medicines Impact Market Access After Formal Licensing? pp. 335-343

Albane Degrassat-Théas, Pascal Paubel, Olivier Parent de Curzon, Claude Pen and Martine Sinègre

Decision-Makers’ Preferences for Approving New Medicines in Wales: A Discrete-Choice Experiment with Assessment of External Validity pp. 345-355

Warren Linley and Dyfrig Hughes

Volume 31, issue 3, 2013

Improving Confidence in Observational Studies pp. 177-179

Eberechukwu Onukwugha

What Evidence Is There for the Reimbursement of Personalised Medicine? pp. 181-183

Peter Hall and Christopher McCabe

Trastuzumab for the Treatment of HER2-Positive Metastatic Gastric Cancer pp. 185-194

Eldon Spackman, Stephen Rice, Gill Norman, Dong-Churl Suh, Alison Eastwood and Stephen Palmer

Cost Effectiveness of Antiarrhythmic Medications in Patients Suffering from Atrial Fibrillation pp. 195-213

Bernd Brüggenjürgen, Stefan Kohler, Nadja Ezzat, Thomas Reinhold and Stefan Willich

Influence of Pharmacogenomic Profiling Prior to Pharmaceutical Treatment in Metastatic Colorectal Cancer on Cost Effectiveness pp. 215-228

Martin Frank and Thomas Mittendorf

The Evaluation and Use of Economic Evidence to Inform Cancer Drug Reimbursement Decisions in Canada pp. 229-236

Jean Yong, Jaclyn Beca and Jeffrey Hoch

The Economic Burden of Depression in Switzerland pp. 237-250

Yuki Tomonaga, Josef Haettenschwiler, Martin Hatzinger, Edith Holsboer-Trachsler, Michael Rufer, Urs Hepp and Thomas Szucs

The State of Health Economic Research in South Africa pp. 251-253

Jeff Gow, Michael Strauss and Alan Whiteside

The Authors’ Reply to Gow et al.: “The State of Health Economic Research in South Africa” pp. 255-256

Paul Gavaza, Karen Rascati, Abiola Oladapo and Star Khoza

Volume 31, issue 2, 2013

Cost-Effectiveness Acceptability Curves Revisited pp. 93-100

Maiwenn Al

Retigabine for the Adjunctive Treatment of Adults with Partial-Onset Seizures in Epilepsy with and without Secondary Generalization pp. 101-110

Dawn Craig, Stephen Rice, Fiona Paton, David Fox and Nerys Woolacott

Acknowledging Patient Heterogeneity in Economic Evaluation pp. 111-123

Janneke Grutters, Mark Sculpher, Andrew Briggs, Johan Severens, Math Candel, James Stahl, Dirk Ruysscher, Albert Boer, Bram Ramaekers and Manuela Joore

A Systematic Review of the Cost Effectiveness of Herpes Zoster Vaccination pp. 125-136

Thomas Szucs and Alena Pfeil

When Does NICE Recommend the Use of Health Technologies Within a Programme of Evidence Development? pp. 137-149

Louise Longworth, JiHee Youn, Laura Bojke, Stephen Palmer, Susan Griffin, Eldon Spackman and Karl Claxton

Improving Clinical Reality in Chronic Obstructive Pulmonary Disease Economic Modelling pp. 151-161

Yumi Asukai, Michael Baldwin, Tiago Fonseca, Alastair Gray, Laura Mungapen and David Price

Valuing Benefits to Inform a Clinical Trial in Pharmacy pp. 163-171

Michela Tinelli, Mandy Ryan, Christine Bond and Anthony Scott

Comparing Subsidized Access to Medicines Across Payer Systems pp. 173-174

Michael Wonder and Richard Milne

The Authors’ Reply to Wonder and Milne: “Comparing Subsidized Access to Medicines Across Payer Systems” pp. 175-176

Rajan Ragupathy, Katri Aaltonen, June Tordoff, Pauline Norris and David Reith

Volume 31, issue 1, 2013

Operationalizing Value-Based Pricing of Medicines pp. 1-10

Jon Sussex, Adrian Towse and Nancy Devlin

Reference Pricing and Price Negotiations for Innovative New Drugs pp. 11-14

Afschin Gandjour

Pazopanib for the First-Line Treatment of Patients with Advanced and/or Metastatic Renal Cell Carcinoma pp. 15-24

Mary Kilonzo, Jenni Hislop, Andrew Elders, Cynthia Fraser, Donald Bissett, Samuel McClinton, Graham Mowatt and Luke Vale

A Systematic and Critical Review of the Evolving Methods and Applications of Value of Information in Academia and Practice pp. 25-48

Lotte Steuten, Gijs Wetering, Karin Groothuis-Oudshoorn and Valesca Retèl

The Humanistic and Economic Burden of Systemic Lupus Erythematosus pp. 49-61

Rachel Meacock, Nicola Dale and Mark Harrison

Cost Effectiveness of First-Line Oral Antiviral Therapies for Chronic Hepatitis B pp. 63-75

María Buti, Itziar Oyagüez, Virginia Lozano and Miguel Casado

Timely and Complete Publication of Economic Evaluations Alongside Randomized Controlled Trials pp. 77-85

Joanna Thorn, Sian Noble and William Hollingworth

A Comment on Boyers et al.: “Eltrombopag for the Treatment of Chronic Immune or Idiopathic Thrombocytopenic Purpura: A NICE Single Technology Appraisal” pp. 87-89

Rachel Allen, Andres Brainsky, Kelly Grotzinger and Tito Roccia

The Authors’ Reply to Allen et al.: “A Comment on Boyers et al.: ‘Eltrombopag for the Treatment of Chronic Immune or Idiopathic Thrombocytopenic Purpura: A NICE Single Technology Appraisal’” pp. 91-91

Dwayne Boyers, Xueli Jia, David Jenkinson and Graham Mowatt